Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
A triplet for multiple myeloma has shown promising safety and efficacy in elderly patients ineligible for transplant.
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.
Ola Landgren, MD, PhD, discusses three studies on quadruplet therapy presented at the 2024 ASCO Annual Meeting.
Advertisement
Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.
Drs. Hira Mian and Manni Mohyuddin join the hosts of "Blood Cancer Talks" for an overview of myeloma maintenance therapy.
Cilta-cel is now indicated for adult patients who have received at least one prior line of therapy.
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
The expansion of the indication was supported by positive data from the KarMMa-3 study.
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
The 11-member panel of independent experts voted eight in favor and three against.
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.